1. Academic Validation
  2. Hippo-signaling-controlled MHC class I antigen processing and presentation pathway potentiates antitumor immunity

Hippo-signaling-controlled MHC class I antigen processing and presentation pathway potentiates antitumor immunity

  • Cell Rep. 2024 Mar 23;43(4):114003. doi: 10.1016/j.celrep.2024.114003.
Linyuan Peng 1 Liang Zhou 2 Huan Li 2 Xin Zhang 1 Su Li 1 Kai Wang 1 Mei Yang 1 Xiaoyu Ma 1 Danlan Zhang 2 Siliang Xiang 1 Yajun Duan 1 Tianzhi Wang 1 Chunmeng Sun 3 Chen Wang 1 Desheng Lu 4 Minxian Qian 5 Zhongyuan Wang 6
Affiliations

Affiliations

  • 1 State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China.
  • 2 Guangdong Provincial Key Laboratory of Regional Immunity and Diseases, Cancer Research Center, Department of Pharmacology, Shenzhen University Medical School, Shenzhen 518055, China.
  • 3 State Key Laboratory of Natural Medicines, NMPA Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipients, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
  • 4 Guangdong Provincial Key Laboratory of Regional Immunity and Diseases, Cancer Research Center, Department of Pharmacology, Shenzhen University Medical School, Shenzhen 518055, China. Electronic address: delu@szu.edu.cn.
  • 5 State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China. Electronic address: qmx@cpu.edu.cn.
  • 6 State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China. Electronic address: wangzhongyuan@cpu.edu.cn.
Abstract

The major histocompatibility complex class I (MHC class I)-mediated tumor antigen processing and presentation (APP) pathway is essential for the recruitment and activation of cytotoxic CD8+ T lymphocytes (CD8+ CTLs). However, this pathway is frequently dysregulated in many cancers, thus leading to a failure of immunotherapy. Here, we report that activation of the tumor-intrinsic Hippo pathway positively correlates with the expression of MHC class I APP genes and the abundance of CD8+ CTLs in mouse tumors and patients. Blocking the Hippo pathway effector Yes-associated protein/transcriptional enhanced associate domain (YAP/TEAD) potently improves antitumor immunity. Mechanistically, the YAP/TEAD complex cooperates with the nucleosome remodeling and deacetylase complex to repress NLRC5 transcription. The upregulation of NLRC5 by YAP/TEAD depletion or pharmacological inhibition increases the expression of MHC class I APP genes and enhances CD8+ CTL-mediated killing of Cancer cells. Collectively, our results suggest a crucial tumor-promoting function of YAP depending on NLRC5 to impair the MHC class I APP pathway and provide a rationale for inhibiting YAP activity in immunotherapy for Cancer.

Keywords

CP: Cancer; CP: Immunology; Hippo pathway; MHC class I; NLRC5; NuRD complex; TAZ; TEAD; YAP; antigen processing and presentation; antitumor immunity; immune checkpoint blockade.

Figures
Products